^
    Back
    Association details:
    Biomarker:CAPZA2-MET fusion + MET amplification
    Cancer:Cholangiocarcinoma
    Drug:Tabrecta (capmatinib) (c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    The Oncologist
    Title:

    Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma

    Published date:
    01/18/2023
    Excerpt:
    We present the case of a patient with chemotherapy-refractory metastatic cholangiocarcinoma harboring a CAPZA-2-MET fusion along with MET amplification who dramatically responded to capmatinib, a specific MET tyrosine kinase inhibitor.
    DOI:
    https://doi.org/10.1093/oncolo/oyac194